Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem

Finerenone protects kidneys in patients with T1D + CKD
Finerenone significantly reduces albuminuria vs placebo and maintains a manageable safety profile in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) receiving background therapy with renin-angiotensin-aldosterone system inhibitors (RAASi), the phase III FINE-ONE trial has shown. These findings represent an important step forward since RAASi were introduced for renoprotection in T1D more than 30 years ago.

Is red meat a risk factor for MASLD?
High consumption of red meat appears to increase the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), but only in men, particularly at intake levels ranging from 75 to 90 g/day, reveals a recent study.

Early intensive lipid-lowering with evolocumab cuts CV events in high-risk primary prevention patients
In the prespecified subgroup analysis of the VESALIUS-CV trial, evolocumab significantly reduced the risk of first major adverse cardiovascular (CV) events (MACE) in individuals without known significant atherosclerosis and with diabetes.





